Climb Bio Announces First Patients Dosed In Budoprutug PrisMN Phase 2 Trial In pMN; Anticipates Data-Rich 2026, With Initial Readouts From All Ongoing Budoprutug And CLYM116 Studies
Benzinga Newsdesk 10 months ago
News
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026
Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China
First patients dosed in CLYM116 Phase 1 healthy volunteer study
Anticipating a data-rich 2026, with initial readouts from all ongoing budoprutug and CLYM116 studies
Strong financial position with cash runway expected into 2028
WELLESLEY HILLS, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced progress updates for its budoprutug and CLYM116 programs. The Company also highlighted its strategic priorities and key anticipated milestones for 2026 and refreshed its financial guidance.